GRIN2A and Encephalopathy: L‐serine, a precursor of the NMDAR co‐agonist, D‐serine, has been trialed in children with encephalopathy associated with LOF GRIN2A/GRIN2B mutations, and reported to improve seizure frequency, behavior, and neuro‐cognitive skills.49